My research career has been focused on platform or drug product developments in the industry settings. I have >20 years of research and development experience in biotech or pharmaceutical companies. My R&D experiences include strategic planning from proposal of new targets and new disease indications to prioritizing the company pipelines to fit for the companies’ business goals. During my career in R&D of the industry, I acquired technical expertise in the areas of cell-based, reporter-based and biochemical assay development using variety readouts such as fluorescent, luminescent, label-free and high content, FACS, High Throughput Screening (HTS), cytoflow assay and immunoassay. I have worked with multidiscipline teams, such as chemistry, pharmacokinetics, and toxicology and acquired cross functional knowledge of drug discovery and development such as hit identification, lead optimization, mechanism of action (MOA), pharmacology, PK/ADME and preclinical development. I also have experience in clinical development spanning Pre-IND meeting with US FDA (2018), IND preparation and filing with MFDS (Korean FDA), IND preparation (2019 and 2021) for US filing, initiating and completion of Phase 1 trial, and managing translational science of Phase 1 trial of oncology.